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ABSTRACT 
ISOLATION OF EGFR-CONTAINING EARLY ENDOSOMES  
Julie A. Gosney 
June 14, 2016 
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase 
(RTK) that is an integral component of proliferative signaling.  When activated by 
a ligand at the plasma membrane, EGFR undergoes clathrin-mediated 
endocytosis.  This spatial regulation of the receptor is an important regulator of 
receptor expression as it mediates its degradation.  Endocytosis also has 
implications on EGFR downstream signaling, though the details are not fully 
understood.  The goal of this thesis is to develop a method to isolate early 
endosomes in order to study downstream effectors associated with activated 
EGFR in this compartment.  HeLa cells were used to test various subcellular 
fractionation methods, optimizing each step to develop a protocol that enriches 
early endosomes.  The isolated compartments were then analyzed by mass 
spectrometry to characterize the protein composition of early endosomes, with 
the goal of further understanding how the spatial regulation of EGFR affects its 
downstream signaling. 
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INTRODUCTION 
 
The study of growth factors and their receptors is a rapidly growing field of 
research that began in the 1960s when Stanley Cohen and Rita Levi-Montalcini 
discovered the first growth factors: Nerve Growth Factor (NGF) and Epidermal 
Growth Factor (EGF) [1, 2].  NGF and EGF are small proteins that stimulate the 
growth of nerve and epithelial cells, respectively.  Before the discovery of growth 
factors, scientists knew that cells could signal for growth and proliferation, 
particularly during development—but they didn’t understand how this 
phenomenon occurred [1].  The identification of NGF and EGF was pivotal, as 
these proteins could now be studied directly in order to elucidate their functions 
in cellular and organ physiology [3].  These discoveries were a major scientific 
breakthrough that earned Cohen and Levi-Montalcini a shared Nobel Prize in 
1986 [4]. 
 Upon Levi-Montalcini’s discovery of NGF, she and Cohen worked 
diligently to understand its function.  Because NGF was discovered in the 
submaxillary glands of mice, they continued using these extracts to study its 
effects on neuronal growth [5].  However, injecting mouse salivary gland extracts 
into newborn pups ended up yielding other, unexpected phenotypes.  Cohen 
noted that these new changes were not due to the induction of nerve growth, but 
due to changes in epithelial tissues [2].  During Cohen’s original experiments  
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characterizing his novel epithelial tissue-specific growth factor, he referred to the 
protein as the “tooth-lid factor” [2].  While the title was only temporary until he 
coined the name EGF, the “tooth-lid factor” was so named because it directly 
described the effects he saw in mice injected with EGF:  it increased the rates of 
tooth growth and eyelid opening in newborn pups [2]. 
 The discovery and characterization of growth factors led to another 
essential discovery—growth factor receptors.  Once Cohen had discovered EGF, 
he immediately began working to isolate and identify its receptor.  In 1982 Cohen 
successfully isolated and characterized EGF’s cognate receptor from mouse 
livers [3].  In this work, the receptor was identified as a 170kDa glycoprotein with 
intrinsic tyrosine kinase activity.  Over the next three decades, the EGF-receptor 
would be studied extensively, leading to our most current understandings of the 
signaling, trafficking, regulation, and physiologic implications of this protein. 
Epidermal Growth Factor Receptor (EGFR) 
The epidermal growth factor receptor (EGFR) is a membrane spanning 
receptor tyrosine kinase (RTK) that is an integral component of proliferative 
signaling.  Part of the ErbB family of receptors, EGFR is also referred to as 
ErbB1 or Her1.  The other ErbB family members include ErbB2 or Her2, ErbB3, 
and ErbB4.  Structurally, EGFR and the ErbB receptors are made up of three 
domains:  1) the extracellular ligand binding domain, 2) the transmembrane alpha 
helices, and 3) the intracellular domain which contains the kinase domain and 
multiple tyrosine residues on the C-terminus (Figure 1).  The extracellular 
domain contains two ligand-binding regions that alternate with two cysteine-rich  
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Figure 1.  Epidermal Growth Factor Receptor structure.  When unbound by a 
ligand, the receptor is often found in a “closed” conformation in which the 
cysteine-rich regions of the extracellular region interact.  When a ligand is 
introduced it binds to the two ligand binding domains and a conformational 
change occurs, exposing a cysteine-rich region which can then interact with an 
exposed cysteine-rich region of another ligand-bound ErbB family receptor.  
Red=inactive kinase domain; green=active kinase domain; orange=ligand binding 
domains; blue=cysteine-rich domains. 
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regions.  Binding of one of EGFR’s seven endogenous ligands—epidermal 
growth factor (EGF), heparin-binding EGF-like growth factor (HBE), epiregulin 
(EPR), epigen, transforming growth factor alpha (TGFα), amphiregulin (AR), and 
betacellulin (BTC)—to the extracellular region induces a conformational change 
in which the ligand binding regions directly interact with the ligand [6].  This 
structural change exposes the two cysteine-rich domains, allowing the receptor 
to associate with the exposed cysteine-rich domains of another ligand-bound 
EGFR or ErbB family RTK monomer to form a dimer [6].  
The binding of two ligand-bound receptors causes the formation of a 
dimer, which is required for receptor activation [7].  The dimer pair interaction 
structurally induces the activation of the kinase domains.  The kinase domain of 
one receptor then phosphorylates the C-terminal tyrosine residues of its dimer 
partner (transphosphorylation) [7].  The cytosolic phosphorylated tyrosine 
residues of the EGFR serve as docking sites for effector molecules that contain 
phosphotyrosine binding (PTB) or src homology 2 (SH2) domains [8].  Proteins 
that dock to the phosphorylated tyrosine residues of an activated EGFR will 
recruit and/or activate other proteins, thus inducing a signaling cascade.  For 
example, at the plasma membrane, an activated EGFR dimer will recruit the 
scaffolding proteins Shc and Grb2 to bind to phosphotyrosines and the EGFR 
kinase domains phosphorylate these proteins [8].  Activation of Grb2 leads to the 
recruitment of SOS and induction of the Ras-ERK pathway which is known to 
activate cell proliferation [8].  Activation of Shc leads to induction of the JNK 
pathway which is also known to be involved in the induction of cell proliferation  
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via the activation of nuclear transcription factors [8].  
EGFR Physiology 
EGFR signaling plays critical roles in cell proliferation, migration, 
differentiation, wound healing, development, and tissue homeostasis.  Growth 
factors are mitogens, and the EGFR is an important mitogenic signal transducer.  
In fact, the EGFR is an essential component of cellular physiology and is critical 
for proper tissue development.  In 1995, Miettinen et al. produced a line of EGFR 
knockout mice to determine the physiologic importance of the receptor in 
development [9].  They found that the knockout (-/-) pups only survived for eight 
days after birth.  The mice also had significant developmental impairments in 
multiple epithelial tissues and organs including the lungs, skin, and 
gastrointestinal tract [9].  In 1999 Miettinen also documented that EGFR (-/-) 
pups have compromised craniofacial development (Figure 2) [10].  EGFR is 
clearly a crucial component for normal tissue development and homeostasis 
throughout the body. 
While the absence or reduction of EGFR signaling unquestionably causes 
severe developmental impairments as discussed, excessive EGFR signaling also 
has detrimental effects.  It has been well documented that the receptor is often 
overexpressed and/or over-activated in many different cancer types, including 
non-small cell lung cancer, breast, pancreatic, cervical, head and neck, and 
colorectal cancer among others [11-16].  Non-small cell lung cancer (NSCLC) is 
the most common type of lung cancer, accounting for about 85% of all lung 
cancers [17].  Many driver mutations have been discovered in NSCLC patients,  
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Figure 2.  The effects of EGFR knockout on craniofacial development in 
mice.  a) A wild-type newborn mouse has a round snout, whereas b) an EGFR (-
/-) mouse has a narrower snout.  c) The nostrils of wild-type mice are open 
(arrow), d) but are often closed or narrow (arrow) in EGFR (-/-) mice.  e)  A wild-
type mouse at four months of age has long whiskers and a well-shaped snout, 
whereas f,g) EGFR (-/-) mice have smaller lower jaws (arrows), deformed eyes, 
and short, curly whiskers.  (from Nature Genetics (1999), 22, 69-73) 
 
 
 
 
 
 
7 
and EGFR is the driver mutation in about 50% of patients who are “never 
smokers” [18].  With a 5-year survival rate of only 17% [19], lung cancer has one 
of the highest mortality rates of all cancer types [17].  Clearly there is a great 
need for better lung cancer treatments, and the EGFR is a model candidate to 
target in these cancers. 
There are currently several FDA-approved anti-EGFR cancer therapies on 
the market.  These drugs are generally split up into two classes—monoclonal 
antibodies and kinase inhibitors.  The monoclonal antibodies (e.g. Cetuximab) 
target the extracellular portion of the receptor and block the interaction of the 
receptor with extracellular activating ligands.  Cetuximab is approved for the 
treatment of cancers that express high levels of EGFR, including colorectal and 
head and neck cancers [20].  Tyrosine kinase inhibitors (TKIs) (e.g. Erlotinib) are 
small molecules that enter the cell and bind (reversibly or irreversibly) to the 
kinase domain of the receptor, blocking effector activation and downstream 
signaling cascades.  Erlotinib is approved for use in NSCLC patients whose 
cancers express EGFR kinase activating mutations, including exon 19 deletion 
and exon 21 (L858R) substitution mutations [18].  While these drugs tend to be 
very effective initially for patients whose cancers express over-activated 
receptors, eventually all of these patients will develop resistance to the drugs 
[21].  The exact mechanism by which this resistance occurs is unclear, although 
several studies suggest that the inhibited receptors can form heterodimers with 
other ErbB family members and even the insulin-like growth factor type-1 
receptor (IGF-1R), another RTK with mitogenic effects [22].   
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Although significant advances in cell biology research have led to the 
development of targeted therapeutics such as the anti-EGFR cancer drugs, these 
therapies provide an overall survival increase of only a few months for these 
subsets of cancer patients [23].  This lack of improvement, coupled with the 
resistance that develops from these treatments, reveals that there is an 
enormous gap in our understanding of mitogenic signaling.  If more robust cancer 
treatments are to be developed, it is essential that the mechanisms driving the 
proliferation and metastasis of these cells are elucidated.  Because targeting the 
EGFR directly has yielded only a minimal benefit to patient outcomes, it would be 
prudent to find more specific targets within the receptor’s signaling pathways.  
Unfortunately, there are still many facets to EGFR signaling that have yet to be 
elucidated.  One such question that could play an important role in understanding 
EGFR downstream signaling is:  how does the spatial regulation of the receptor 
affect its signaling?  This is the primary question we seek to answer in this work.  
EGFR Regulation 
The major mechanism through which the EGFR is regulated is the 
endocytic pathway (Figure 3).  Once the activated dimer is formed it migrates to 
a clathrin-rich region of the plasma membrane where it invaginates and pinches 
off into a clathrin-coated vesicle.  The clathrin is then shed, and this intermediate 
vesicle fuses with an early endosome [24].  The early endosome, sometimes 
referred to as the signaling or sorting endosome, is the epicenter of endocytic 
trafficking.  This organelle is responsible for determining the fate of its contents, 
depending on several factors including what ligand is bound and with which ErbB 
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Figure 3.  Endocytic trafficking of the EGFR.  The EGFR undergoes ligand-
dependent, clathrin-mediated endocytosis.  Early endosomes either mature into 
late endosomes where their contents are transported to lysosomes for 
degradation, or the receptor can be trafficked back to the plasma membrane via 
a recycling endosome.  The increasing acidity of these compartments induces 
dissociation of the ligand:receptor complex.  The EGFR can continue to elicit 
signaling cascades from the early endosome.  Red=ligand, green=active kinase 
domain, orange=clathrin. 
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family member the EGFR is dimerized.  The early endosome can send proteins 
back to the plasma membrane (recycling) [25], or sequester cargo to be sent to 
and degraded in a lysosome [26].  It has been reported that endocytosis can also 
transport EGFR to the endoplasmic reticulum and the nucleus [27, 28].  Over 
time early endosomes increase in acidity and “mature” into late endosomes [29].  
The late endosomes will fuse with a lysosome, where the receptor is degraded 
and thus down-regulated.  It is important to note that while in the early endosome 
the kinase domain of the receptor remains exposed to the cytosol, allowing the 
receptor to continue interacting with other proteins and downstream effectors 
[30]. 
Until the 1990s, EGFR spatial regulation by the endocytic pathway was 
viewed primarily as a mechanism for downregulating receptor expression after 
activation.  Chen et al. discovered in 1989 that an 18 amino acid sequence of the 
EGFR C-terminus is required for both kinase activation and internalization/ 
downregulation of the receptor [31].  Shortly thereafter in 1990, Wells et al. 
discovered that EGFRs that cannot undergo endocytosis enhance cell 
transformation [7].  They concluded from this study that without endocytosis, the 
receptor cannot be degraded and thus increases ligand-dependent cell 
transformation.  As such, endocytosis was viewed as a negative regulator of 
EGFR expression.  However, in 1994 Bergeron’s group discovered that certain 
EGFR scaffolding proteins involved in Ras signaling (i.e. Shc, Grb2, and mSOS) 
retain their association with active EGFR when it is internalized [25].  Further, in 
1996, Vieira et al. created an endocytosis-defective cell line to study the changes 
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in EGFR downstream effector activation after EGF treatment.  They found that 
blocking EGFR endocytosis enhanced PLCγ and Shc phosphorylation, but 
decreased ERK1/2, EGFR, & PI3K phosphorylation [26].  These works, among 
others, pushed the field of EGFR trafficking towards a new line of thinking: 
endocytosis can positively and negatively affect receptor:effector communication.  
However, there is currently no consensus on how these changes occur, or how 
they contribute to EGFR signaling and overall cellular physiology. 
It has been well established that the endocytic pathway is important in the 
spatial as well as temporal regulation of the EGFR.  The receptor is regulated 
temporally by the amount of time it takes to traverse the entire endocytic 
pathway, and how long the receptor is sequestered at each point of the pathway.  
About 10% of a cell’s inactive EGFRs are constitutively recycled into early 
endosomes and back to the plasma membrane [32].  It has also been shown that 
different ligands induce varied endocytic responses.  For example, it is known 
that TGFα triggers rapid recycling of the receptors, while EGF triggers the 
receptor to be maintained in early endosomes, leading to its eventual 
degradation and downregulation [33].   
One explanation for these distinct differences in ligand:receptor trafficking 
amongst ligands is their affinity for the receptor.  EGF is known to have a 
relatively high affinity for binding EGFR of 0.42nM [34], and thus does not 
dissociate from the receptor in the acidic environment of early endosomes (pH 
6).  However, TGFα has a slightly lower affinity for the receptor at 11.9nM [34], 
causing the ligand:receptor complex to dissociate in early endosomes, permitting 
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receptor recycling to the plasma membrane [33].  Though both ligands are 
considered to have “high” affinities for EGFR [35], they do not have the same 
effects on receptor trafficking.  Conversely, the work of Moriai et al. suggests that 
EGF and TGFα have similar affinities for EGFR, and that certain mutations in the 
ligand binding domain of some EGFRs may contribute to the different binding 
affinities and downstream signaling effects of ligands [36]. 
The Endocytic Pathway 
 The endocytic pathway is a complex and dynamic system made up of 
various organelles [37].  Endocytosis is a fundamental cellular process in which 
extracellular nutrients and portions of the plasma membrane are internalized into 
the cell [37].  A section of plasma membrane will invaginate and pinch off to form 
an intracellular vesicle [37].  These preliminary vesicles are typically formed with 
the assistance of several adaptor and scaffolding proteins that are found near or 
on the plasma membrane [38].  For example, clathrin-mediated endocytosis 
(CME) requires the cytosolic protein clathrin, which forms a triskelion coat around 
the portion of plasma membrane that is to be internalized [38].  This process also 
requires another protein called dynamin that plays a critical role in the scission of 
the new vesicle from the plasma membrane [38].  CME is also referred to as 
receptor-mediated endocytosis, as it occurs when a plasma-membrane receptor 
is bound and activated by an extracellular ligand, triggering its internalization 
(e.g. EGF binding to EGFR) [38].  During CME, after the new vesicle is created 
the clathrin coat is shed.  This intermediate vesicle is then trafficked to and fused 
with an endosome, of which there are several types [38].  The destination of each 
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vesicle is specific to its cargo and has a direct impact on the fate of that cargo.  
This process is highly regulated by actin filaments and microtubules, adaptor 
proteins, and GTPases such as the RAB proteins [38].  The RAB family of 
proteins are Ras-like GTPases that play an essential role in the endocytic 
pathway by recruiting effectors that induce the formation and motility of 
endosomes [39].  There are more than 60 different RAB proteins, and each one 
is generally specific to a distinct cellular compartment [40].  In 1990, Chavrier and 
Zerial determined that RAB5 is specific to the plasma membrane and early 
endosomes, and RAB7 localizes to late endosomes [41].  RAB11 is another 
member of the RAB family that is specifically localized to recycling endosomes 
[42].  These three RAB proteins are the major players involved in generating the 
vesicles involved in the early phases of endocytosis (i.e. early, late, and recycling 
endosomes). 
 Clathrin-mediated endocytosis is the primary pathway by which activated 
EGFR enters early endosomes when stimulated with low, endogenous 
concentrations of ligand (i.e. ~1ng/mL or 0.16nM EGF) [43].  However, there are 
other types of endocytosis that utilize adapter proteins similar to clathrin.  For 
example, caveolae are small pits in the plasma membrane made up of lipid rafts 
and the protein caveolin [44].  Caveolae are also involved in the endocytosis of 
plasma membrane and extracellular ligands and nutrients.  This process is 
similar to CME, as it also requires dynamin for the scission and formation of 
vesicles [38].  It also differs from CME in that caveolae cargo can either be 
delivered to early endosomes or to caveosomes [44].  Caveosomes are pH-
14 
neutral intracellular vesicles that strictly contain cargo transported from caveolae, 
and they do not contain early endosome proteins, although their function is 
similar to early endosomes [44].  There are other routes of endocytosis that do 
not involve clathrin or caveolae, which are collectively termed clathrin- and 
caveolae-independent endocytosis [38].  The major routes of EGFR-endocytosis 
are CME at low ligand concentrations, and caveolae-mediated endocytosis 
(CavME) at high ligand concentrations (i.e. >10ng/mL or >1.6nM EGF) [43].  
 Whether via CME or CavME, most endocytic cargo will be transported into 
early endosomes.  Early endosomes are so named because they are found in 
the cytosol near the plasma membrane, and they are the first major constituent 
within the endocytic pathway.  These organelles are considered to be slightly 
acidic, with a pH of ~6.0 and a density of 1.035-1.042g/mL [29, 45].  Early 
endosomes are the first pit-stop in the pathway, and the sequestration of 
receptors here is critical to their ultimate fate.   
There are two distinct populations of early endosomes: dynamic and 
static.  In 2006 Lakadamyali and Rust discovered and characterized these types 
of endosomes by their mobility and maturation kinetics [46].   To do this, RAB5 
and RAB7 were fluorescently tagged and the association of these proteins with 
various ligands that undergo CME were tracked using live cell imaging.  They 
found that the static population of early endosomes are the most abundant, and 
they mature very slowly.  The dynamic early endosomes are strongly associated 
with microtubules and mature rapidly into late endosomes.  Remarkably, 
ligand:receptor complexes that are normally degraded via the endocytic pathway, 
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such as EGF:EGFR and low density lipoprotein and its cognate receptor 
(LDL:LDLR), were preferentially trafficked into the dynamic population of early 
endosomes.  On the other hand, complexes that are typically recycled, such as 
transferrin and its receptor (Tfn:TfnR), were trafficked non-specifically to both 
populations of early endosomes [46].  This study provides further evidence that 
the endocytic pathway is highly regulated and the fate of every cargo that enters 
is tightly monitored.   
 As evidenced by the fates of the EGFR and TfnR, early endosomal 
contents can be segregated into various legs of the endocytic pathway.  Certain 
proteins that are marked for recycling back to the plasma membrane can be sent 
directly to the cell membrane by an intermediate vesicle, or trafficked to a larger 
specialized vesicle called the recycling endosome [37].  Contents that are not 
recycled will remain sequestered in early endosomes.  The organelles that 
comprise the endocytic pathway possess proton pumps on their membranes that 
maintain their luminal pH [29, 47].  However, over time these pumps will increase 
the acidity of early endosomes.  This is a crucial step in the “maturation” process 
of an early endosome into a late endosome [48].   
Late endosomes are also termed “multivesicular bodies” or MVBs, and 
have an acidic pH of ~5.3 and a density of 1.048-1.070g/mL [29, 45].  The name 
MVBs comes from the presence of intraluminal vesicles that are created within 
the organelle [49].  These are small, membrane-bound vesicles that are 
internalized from the outer membrane of the late endosome itself, which is also 
referred to as the “limiting membrane” [49].  Receptors and other cargo found in 
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the late endosome that are to be degraded are marked as such by entering into 
these intraluminal vesicles [49].  There are specific protein complexes called 
ESCRTs (endosomal sorting complex required for transport) that are required for 
the transport of cargo from the limiting membrane into intraluminal vesicles of 
late endosomes [50].  ESCRT complexes specifically interact with ubiquitinated 
cargo within the late endosome, as ubiquitination marks proteins for degradation 
[50].  Once a cargo is sequestered into an intraluminal vesicle, it is destined to be 
transported to a lysosome where it will be degraded.  The late endosome will 
temporarily fuse with a lysosome and transfer its contents (intraluminal vesicles) 
to the lysosome [51].   
Lysosomes are separate organelles that have a pH of ~5.0 and a density 
of between 1.070-1.110g/mL [29, 45].  The sole purpose of a lysosome is to 
degrade proteins, as they are filled with acid hydrolases to break down cargo 
[51].  This compartment is the final stop in the endocytosis of cargo that is 
marked for degradation (i.e. ubiquitinated).  This degradation process is essential 
for the down-regulation of a multitude of cellular components, including signaling 
receptors like EGFR [51].   
The focus of this project is the mitogenic signaling of EGFR from early 
endosomes.  EGFR bound and activated by EGF is trafficked through the 
endocytic pathway to ultimately be degraded by a lysosome.  Further, the kinase 
domain remains active and associated with the cytosol until the receptor is 
trafficked into the intraluminal vesicles of late endosomes.  Our ultimate goal is to 
understand what specific signals are regulated by the early endosomal 
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association of an active EGFR.  In order to study this, our immediate goal and 
the focus of this thesis is to develop a protocol for isolating early endosomes. 
Endosome Isolation Methods 
 A multitude of labs have studied the biochemical properties of various 
endosomes, and have done so by isolating and separating endosomes from 
cells.  The process of breaking open cells to separate out and study specific 
intracellular compartments is termed subcellular fractionation.  Subcellular 
fractionation can be applied and modified in many ways to study the contents 
and functions of the various endocytic organelles.  In this chapter, these methods 
will be outlined to determine the strengths and weaknesses of each method.   
 The process of subcellular fractionation is generally made up of three 
parts: lysing cells, separating cytosolic organelles, and isolating the target 
organelle [52].  There are several ways to perform these steps, each of which 
must also be optimized for the type of cells being used.  Subcellular fractionation 
can be utilized to study virtually any organelle or compartment inside cells.  
However, the focus of this review will be on the application of these methods for 
isolating endocytic organelles. 
 The first step of subcellular fractionation involves breaking open cells to 
access internal compartments.  The two major methods used to achieve this are 
hypotonic and mechanical lysis.  Hypotonic lysis of cells involves incubating cells 
with a buffer containing lower than physiologic concentrations of either salt or 
sucrose until enough water moves into the cells via osmosis that the cells swell 
and eventually burst.  This is a very effective method for lysing cells, however, if 
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the organelles are continuously exposed to a hypotonic buffer, it is possible that 
the organelles themselves risk being lysed as well.  Some organelles, like 
lysosomes, are sensitive to hypotonic lysis, while others like early endosomes 
are not [53].   
The second option for lysing cells is to use mechanical disruption.  This 
can be achieved by passaging cells through a syringe and a small needle 
(typically 20-25 gauge), a ball-bearing homogenizer, or exposing cells to 
sonication.  All of these methods work to lyse cells by applying physical force to 
the membrane of the cell.  This method is less invasive than a hypotonic buffer 
and is generally considered to have little effect on the integrity of the intracellular 
compartments.  However, it has been documented that these mechanical 
techniques can cause the formation of new, non-physiologically relevant vesicles 
as a result of hybrid fusion of distinct organelles [54].  The pros and cons of both 
of these lysis methods should be considered when selecting a lysis method for 
subcellular fractionation.   
 The second step of subcellular fractionation is separating intracellular 
components.  Typically after lysis, the cell lysates will be gently centrifuged to 
pellet and remove large debris and nuclei.  The nuclei can be discarded or used 
for further analysis of nuclear proteins or DNA.  The resulting supernatant 
contains all cytosolic organelles, proteins, cytoskeleton, and the broken plasma 
membrane.  This is referred to as the post-nuclear supernatant (PNS).  The 
contents of the PNS must then be separated out to make the target organelle  
more accessible for the final isolation step of subcellular fractionation.   
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The most common methods of organelle separation utilize centrifugation.  
There are two widely used types of centrifugation—rate zonal or differential, and 
isopycnic.  Rate zonal/differential centrifugation separates samples by size, and 
isopycnic/density centrifugation separates samples by density.  Creating a PNS 
from cell lysates utilizes differential centrifugation.  This type of separation can 
also be used to separate any other subcellular compartments based on size.  
Generally, increasingly higher speeds are required to pellet increasingly smaller 
organelles.  Large nuclei require low speeds to pellet (~600 x g), while much 
smaller mitochondria and endosomes require much higher speeds to pellet 
(~10,000-20,000 x g), and still smaller ribosomes and endoplasmic reticulum 
fragments require extremely high speeds to pellet (~100,000 x g) [52].  
Differential centrifugation is typically applied in sequence, beginning with low 
speeds to pellet large organelles and collecting the supernatant to spin at higher 
speeds to pellet smaller organelles.  This process allows rapid and distinct 
separation of target compartments.  However, because several organelles can 
sediment together due to size similarities, further separation methods may be 
necessary for isolation of a pure population of the target organelle.  Differential 
centrifugation has been used for early/late endosome isolation [53, 55], but 
recently isopycnic centrifugation has been more commonly used. 
Isopycnic centrifugation requires the use of media to create a density 
gradient.  One type of density gradient is a continuous gradient.  A continuous 
gradient is typically created with the use of a commercially available 
heterogeneous media.  During centrifugation, the media creates a spontaneous, 
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self-forming gradient throughout the sample tube—the least dense materials will 
migrate to the top of the tube, and the densest materials will migrate to the 
bottom.  Percoll is an example of a commonly used density gradient media for 
isopycnic centrifugation.  Percoll is a mixture of colloidal silica coated with 
polyvinylpyrrolidone.  When cell lysates are mixed with and centrifuged in a 
continuous gradient, organelles migrate to their isopycnic point within the 
gradient.  The gradients can then be collected in multiple “fractions” to separate 
the contents with varying densities.  An advantage of using a continuous gradient 
is the ability to resolve compartments with minute differences in density.  
However, a distinct disadvantage is that samples are diluted within the media, 
decreasing their concentration.  This becomes more of an issue when the target 
organelle exhibits a range of densities and migrates within several fractions of 
the gradient, further decreasing their concentration.  For example, early and late 
endosomes exhibit two separate ranges of densities (i.e. 1.035-1.042g/mL and 
1.048-1.070g/mL, respectively) [45].  Although this increases the range of 
fractions within the gradient that will contain these vesicles, their densities are 
distinct enough to still separate both, with minimal overlap.  Percoll gradients 
have been utilized for decades to separate and isolate endosomes [56-58]. 
The second type of density gradient is a discontinuous gradient.  
Discontinuous gradients are pre-formed and made of layers of media with 
increasing densities.  Sucrose is the most common media used to create a 
discontinuous gradient—also referred to as a “step” gradient.  The final products 
of a discontinuous gradient are distinct “fractions” that can be collected from the 
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“interface” between each layer of media.  The number of interfaces/fractions in 
the gradient is dependent upon the number of layers in the gradient, and the 
quantity and density of the layers can be optimized based on the target 
subcellular compartment being collected.  This is a distinct advantage of using a 
step gradient over a continuous gradient.  The fractions from a discontinuous 
gradient can also be collected in much smaller volumes, providing more 
concentrated samples.  While samples still migrate to their isopycnic point in a 
step gradient, there are a finite number of isopycnic points as they correlate to 
each distinct interface.  As such, compartments collected at each fraction can 
exhibit a wide range of densities.  This feature can serve as either an advantage 
or a disadvantage to this technique, depending on the target compartment.  A 
disadvantage is the increased potential for samples to be contaminated with 
other subcellular organelles.  Sucrose step gradients are also commonly used to 
isolate endosomes [58, 59]. 
The third and final step of subcellular fractionation is purification of the 
target organelle.  Technically, this step is not a requirement for subcellular 
fractionation.  In fact, depending on the scientific question being asked, this step 
is frequently omitted altogether.  In many cases, the separation and enrichment 
of target organelles with density gradients is sufficient for further study with 
biochemical techniques [60, 61].  However, obtaining a pure organelle sample is 
essential for analyzing the proteome of a compartment.  Multiple platforms can 
be used for this step, and it is arguably the most important component of 
organelle isolation.  Typically, in order to isolate a particular cellular 
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compartment, a protein specific to the compartment of interest will be targeted.  
For example, antibodies against RAB11a, a protein specifically associated with 
recycling endosomes, were conjugated to magnetic beads, incubated with 
subcellular fractions, and placed on a magnet to purify recycling endosomes in 
the work of Silvis et al. [59].  The affinity of the antibody for its antigen, as well as 
the substrate to which the antibody is conjugated, are two critical components of 
this method [52].  Magnetic (Dynabeads), sepharose, and agarose beads are 
commercially available binding substrates with either Protein A or Protein G (or a 
mixture of both) coupled to the beads.  Protein A & G are immunoglobulin-
binding proteins that should be selected based on the source of the monoclonal 
antibody they will bind.  The material make-up of the beads (Dynabeads, 
agarose, or sepharose) can also be selected based on their properties.  Agarose 
and sepharose beads must be centrifuged or loaded on a column to isolate the 
beads and their bound organelles.  Dynabeads, however, can be placed on a 
magnet and the supernatant removed with a pipette.  Magnetic beads generally 
provide a gentler platform for isolating the target organelle, however they tend to 
be more expensive.  The target organelles can be eluted off of the beads using 
either pH washes or a protein solubilizing buffer.   
Various modifications of all three steps of subcellular fractionation detailed 
in this chapter were tested in order to develop a protocol optimized for the 
isolation of early endosomes from HeLa cells to study EGFR signaling from these 
compartments.  
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MATERIALS AND METHODS 
Cell Culture 
   HeLa cells were acquired from American Type Culture Collection 
(ATCC).  Cells were cultured at 37°C in 5% CO2 and maintained in Dulbecco’s 
Modified Eagle Medium (DMEM, Gibco) supplemented with 5% Fetal Bovine 
Serum (FBS, Invitrogen), 100U/mL streptomycin, 100U/mL penicillin, and 2mM 
glutamine [62]. 
Cell Lysis Preparation 
 Cells were lysed using either mechanical lysis or osmotic lysis as 
indicated in the text and figure legends.  Cells were grown to confluency in 15cm 
dishes, serum starved for 2 hours at 37°C, then incubated with the indicated 
concentration of EGF ligand (Invitrogen, #PHG0311) and/or carbocyanine dye 
“DiI” (Molecular Probes, #D-282) (dissolved in EtOH) for the indicated amount of 
time immediately prior to harvest. 
1. Mechanical Lysis 
Cell lysates were prepared by washing twice with room temperature (RT) 
PBS and equilibrating to 4°C on ice, followed by scraping into 4mLs of ice-cold 
lysis buffer (PBS supplemented with a cocktail of protease and phosphatase 
inhibitors—2mM PMSF [phenylmethylsulfonyl fluoride], 1μM Na3VO4 [sodium 
orthovanadate], 10μM pepstatin, and 1μM aprotinin).  Cell suspensions were 
pipetted into 0.5mL aliquots (~2.0 x 106 cells) and each aliquot was passaged 15 
24 
times through an Isobiotec metal ball-bearing cell homogenizer (Heidelberg, 
Germany) with a clearance of 14μm at 4°C.  Lysates were pooled together and 
centrifuged at 200 x g for 10’ at 4°C in a JA25.50 rotor (Beckman-Coulter).  The 
post-nuclear supernatant (PNS) was collected from each sample [45]. 
2. Osmotic Lysis  
Cell lysates were prepared by washing twice with RT PBS and 
equilibrating to 4°C on ice, followed by equilibrating in ice-cold lysis buffer (TES-
10mM triethanolamine, 1mM EDTA, 0.25M sucrose pH 7.2).  Cells were 
incubated on ice with TES buffer (supplemented with 2mM PMSF, 1mM Na3VO4, 
10μM pepstatin, and 1μM aprotinin) until cells began to swell, but before bursting 
(approx. 5 minutes), and scraped with a rubber policeman.  The collected cells 
were pipetted up and down 40 times with a P1000 pipet and centrifuged at 200 x 
g for 10’ at 4°C in a JA25.50 rotor to create a post-nuclear supernatant (PNS) 
which was subsequently collected [45].   
Percoll Gradient Fractionation 
 Twenty-four hours prior to experimentation, stock Percoll (GE Healthcare) 
was equilibrated with 2.5M sucrose at a ratio of 9:1.  The 90% Percoll/0.25M 
sucrose solution was stored at 4°C until use.  Samples were prepared as 
indicated (by PNS preparation via either osmotic lysis or mechanical lysis, or by 
sucrose gradient fractionation), and each sample was mixed with the 90% Percoll 
solution (final concentration 17% Percoll) and Percoll buffer (250mM sucrose, 
1mM EDTA, 10mM HEPES in PBS, pH 7.2) or TES to a total volume of 11.5mLs.  
Buffers were spiked with 2mM PMSF, 1mM Na3VO4, 10μM pepstatin, and 1μM 
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aprotinin before use.  PNS/Percoll/Buffer mixtures were pipetted into 16mm x 
67mm OptiSeal™ polypropylene tubes (Beckman Coulter) and loaded into a pre-
chilled VTi65.1 vertical rotor.  Density beads (with known densities in 17% 
Percoll/250mM sucrose) (GE Healthcare) were loaded into a separate tube 
containing 17% isotonic Percoll in buffer and mixed.  Samples were spun in a 
Beckman Coulter Optima L-100 XP Ultracentrifuge at 50,000 x g for 25’ with max 
acceleration and brake.  Samples were then fractionated from the bottom of the 
centrifuge tube in 10-drop aliquots (~330μL) into pre-chilled Eppendorf tubes 
(~30 fractions per gradient) using a peristaltic pump and a glass pipet at 4°C [45].  
For cells that were labeled with DiI, the collected fractions were loaded into a 96-
well dish and read on a fluorescence plate reader (BioTek) (excitation 530/25, 
emission 590/35).  For experiments where fractions were subjected to affinity 
purification, the fractions in which DiI fluorescence peaked were pooled together 
(~6 fractions per condition, ~2mL total) and mixed by inverting and gently 
pipetting up and down.  For experiments where fractions were not pooled but 
analyzed directly via immunoblot, each fraction was diluted in 6X SDS sample 
buffer containing 10% β-mercaptoethanol (βME), boiled at 100°C for 3’, and 
centrifuged at 21,000 x g to pellet Percoll.  The tube containing density beads 
was imaged and Rf values were calculated based on bead migration in the 
gradient.   
Affinity Purification of Early Endosomes 
 Protein G Dynabeads (Invitrogen) were resuspended and washed three 
times in PBS before use.  Approximately 0.22μg of EEA1 monoclonal antibody 
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(Cell Signaling, #3288) was pre-conjugated to ~2.0 x 107 washed magnetic 
beads in an equivalent volume of buffer used for cell lysis by rotating at 4°C for at 
least 2 hours.  The beads were washed again in ice-cold buffer three times to 
remove unbound antibody.  Either pooled DiI peak fractions from Percoll gradient 
samples or HeLa cell PNS (as indicated) were incubated with the EEA1 antibody-
conjugated magnetic beads (~1mL sample per tube of EEA1-conjugated 
magnetic beads) and rotated at 4°C for 1 hour.  Magnetic beads were isolated 
and the first supernatant (pass through, PT) was collected.  The beads were then 
washed two times in ice-cold buffer and eluted in 6X SDS buffer containing 10% 
βME and boiled at 100°C for 3’.  Remaining samples collected were diluted in 6X 
SDS buffer with 10% βME and boiled.  Samples containing Percoll were 
centrifuged at 21,000 x g to pellet Percoll. 
Sucrose Gradient Fractionation 
 Cells were grown to confluency in 15cm dishes, serum starved for 2 
hours, and incubated with the indicated concentration of EGF ligand and/or DiI 
for 15’ immediately prior to harvest.  Cells were washed twice in RT PBS before 
equilibrating to 4°C on ice.  Dishes were equilibrated in ice-cold lysis buffer (1mM 
Tris, 2mM EDTA, pH 7.4) followed by incubation on ice with ice-cold lysis buffer 
(supplemented with 2mM PMSF, 1mM Na3VO4, 10μM pepstatin, and 1μM 
aprotinin) until cells begin to swell, but before they burst (~5’).  Cells were 
scraped with a rubber policeman and pelleted at 800 x g for 3’ in an Allegra 25R 
centrifuge (Beckman Coulter).  The cell pellet was resuspended in 1mL ice-cold 
lysis buffer supplemented with protease inhibitors and passaged 20 times 
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through a 22-gauge (22G) needle and syringe.  Cell lysates (750μL) were loaded 
on top of a pre-loaded sucrose gradient (SW41-14 x 89mm thinwall 
polypropylene tubes [Beckman Coulter]) supplemented with protease and 
phosphatase inhibitors as follows, beginning with the bottom layer: 3.7mL 60% 
sucrose, 4.0mL 38% sucrose, 3.2mL 5% sucrose, 750uL cell lysates.  Tubes and 
buckets were weighed to ensure balance, loaded on an SW41 rotor (Beckman), 
and centrifuged in a Beckman Coulter Optima L-100 XP Ultracentrifuge at 
210,000 x g for one hour with max acceleration and max brake at 4°C.  The milky 
interface between each layer of sucrose was collected, with intracellular vesicles 
at the 5%-38% interface and membranes at the 38%-60% interface.  Samples 
were diluted in 6X SDS buffer with 10% βME and boiled for 3’ at 100°C.   
Immunoblotting 
 Samples were diluted in 6X SDS buffer with 10% βME and boiled at 
100°C for 3’ prior to gel loading.  Samples were loaded as a percentage of total 
sample volume and resolved by SDS-PAGE.  Proteins were then transferred 
onto a nitrocellulose membrane and blocked with 5% milk before probing 
overnight at 4°C with primary antibody, diluted 1:1000.  The following antibodies 
were used for immunoblot detection: EGFR (Santa Cruz, #sc-03), TfnR (BD 
Biosciences, #612124), LAMP2 (University of Iowa Hybridoma Bank, #H4B4), 
EEA1 (BD Biosciences, #610456), Na/K-ATPase (Sigma, #A276-only used 
where indicated), Na/K-ATPase (Cell Signaling, #3010), and Calnexin (BD 
Transduction, #610524).  Membranes were then washed 3 x 10’ in TBS-
Tween20 (TBST) and incubated with the appropriate horseradish peroxidase 
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conjugated secondary antibody (anti-mouse or anti-rabbit, Thermo Fisher-Pierce) 
diluted 1:2500, for one hour at RT.  Membranes were washed again 3 x 10’ in 
TBST and imaged using Enhanced Chemiluminescence on a Fotodyne imaging 
system.  Western blots were quantified using Image J software. 
Indirect Immunofluorescence 
 HeLa cells were grown to confluency on NaOH treated, sterile 12mm 
round glass coverslips.  Cells were serum starved for 2 hours and incubated with 
the indicated concentration of EGF ligand and/or DiI for 15 minutes.  Coverslips 
were washed gently in PBS++ (PBS, 0.5mM CaCl2, 0.5mM MgCl2) and cells were 
fixed in 4% paraformaldehyde/PBS++ for 5’ at RT and 15’ on ice.  After fixation, 
coverslips were removed from ice and washed 3 x 5’ in PBS++.  Cells were 
permeabilized in PBS++++ (0.1% saponin/5% FBS/PBS++) for 20’ at RT and 
washed 3 x 5’ in PBS++.  The indicated primary antibody (1°Ab) [EGFR (Ab-1, 
EMD Millipore, #GR01), EEA1 (BD Biosciences, #610456)] was prepared by a 
1:1000 dilution in PBS++++ and centrifuged for 5’ at 21,000 x g.  Coverslips were 
placed, cell-side down, on top of 30μL aliquots of 1°Ab on a piece of parafilm for 
1 hour at RT.  Coverslips were returned to dishes and washed 3 x 5’ in PBS++.  
The appropriate secondary antibody (2°Ab), either Alexa488- or Alexa568-
labeled (Life Technologies) was diluted 1:200 in PBS++++ and centrifuged at 
21,000 x g for 5’.  Cells were incubated with 2°Ab for 1 hour at RT as described 
for the 1ºAb.  Free Ab was removed with 6 x 10’ washes in PBS++ and coverslips 
were rinsed in ddH2O prior to mounting onto glass slides with Prolong + DAPI 
(Life Technologies) [63].  Slides were cured in the dark overnight before imaging  
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with a 60X oil immersion objective lens on a Nikon Eclipse Ti-E Inverted 
fluorescence microscope, using Nikon NIS Elements software. 
Coomassie Staining 
 Early endosomes immunoprecipitated from HeLa cell PNS were resolved 
on a 7.5% SDS-PAGE.  The gel was rinsed once in ddH2O and covered with 
Coomassie (50% MeOH, 0.05% Coomassie Brilliant Blue R [Sigma], 10% acetic 
acid, 40% ddH2O) and microwaved for 5 seconds.  The gel was incubated with 
Coomassie at RT with gentle rocking for 15’.  The Coomassie was removed and 
the gel was rinsed twice in ddH2O.  The gel was then covered in Destain solution 
(7% glacial acetic acid, 5% MeOH, 88% ddH2O) and incubated overnight at RT 
with gentle rocking.  The gel was rinsed in ddH2O, imaged using a Fotodyne 
imaging system, and stored in 7% acetic acid/ddH2O at 4°C.   
Mass Spectrometry 
1.  In-Gel Protein Digestion 
 This protocol is modified from Jensen, et al., 1999 [64].  A Coomassie 
stained SDS-PAGE gel was cut into 1mm3 plugs and incubated in 100mM 
triethylammonium bicarbonate (TEA-BC, Sigma) at RT for 15’.  Acetonitrile 
(ACN) was added to the TEA-BC solution and the gel plugs were incubated at 
RT for 15’ with gentle vortexing.  The solvent was removed and the washing 
process was repeated until the Coomassie blue stain was no longer visible.  
Solvent was removed and the gel plugs were dried in a SpeedVac for 5’.  The 
dried plugs were incubated in DTT (20mM DTT [BioRad],100mM TEA-BC) at 
56°C for 45’, followed by iodoacetamide (55mM iodoacetamide [Sigma], 100mM 
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TEA-BC) at RT for 30’ protected from light.  Iodoacetamide was removed and 
gels were washed in 50mM TEA-BC at RT for 15’, followed by the addition of 
ACN for 15’ at RT with gentle vortexing.  The gel plugs were again dried for 5’ in 
a SpeedVac, and incubated in digestion buffer (20ng/μL modified Trypsin 
[Promega] in 50mM TEA-BC) for approximately 10’ until the gel plugs swelled.  
After swelling, 50mM TEA-BC was added to the plugs, followed by 37°C 
overnight incubation in a shaker.  Digestion supernatants from the upper and 
lower half of the gel were combined for each sample. 
2. Extraction of Peptides 
 This protocol is modified from Shevchenko, et al. 2006 [65].  LC-MS grade 
water was added to the digested gel plugs to give a final concentration of 25mM 
TEA-BC.  Two volumes of 1:2 5% v/v formic acid:acetonitrile was added and 
incubated at RT for 15’ in a shaker (100rpm in a C25 Incubator Shaker [New 
Brunswick Scientific]).  Liquid surrounding the gel pieces was transferred to a 
clean microtube and dissolved in Chromatography Buffer A (2% v/v 
acetonitrile/0.1% v/v formic acid).  The dissolved sample was filtered through a 
0.45μm regenerated cellulose syringe filter (Thermo #F2504-7) to remove any 
remaining gel material.  Resolubilized gel band digests were desalted and 
concentrated using C18 PROTO™, 300 Å Ultra MicroSpin Column (The Nest 
Group, Inc., Southborough, MA, USA).  Samples were cooled to -80°C, dried 
using a SpeedVac, and redissolved in Chromatography Buffer A.  Sample 
absorbance was read at 205nm using a NanoDrop 2000 spectrophotometer to 
determine peptide concentration.  Sample volumes were adjusted in Buffer A to  
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normalize peptide concentrations to 0.1μg/μL. 
3.  Liquid Chromatography/Mass Spectrometry (LCMS) 
 Gel band digests (0.5µg) were separated on 12cm of Aeris Peptide XB-
C18, 3.6μm, 100Å material (Phenomenex, Torrance, CA, USA) packed into a 
360µm OD x 100µm ID fused silica tip that was pulled using a Model P-2000 
Micropipette Puller (Sutter Instrument Co., Novato, CA, USA).  Peptides were 
eluted from the column using an EASY n-LC UHPLC system (Thermo Fisher 
Scientific, Waltham, MA, USA) in an 80’ linear gradient using Buffer A and Buffer 
B (80% v/v acetonitrile/0.1% v/v formic acid) as mobile phases (from 0% Buffer B 
to 50% Buffer B).  The samples were then separated by a 5’ linear gradient from 
50% Buffer B to 95% Buffer B, followed by a 5’ wash in 95% Buffer B.  The 
sample was introduced into the LTQ-Orbitrap Elite (ThermoElectron) mass 
spectrometer by nanoelectrospray using a Nanospray Flex source 
(ThermoElectron).  The ion transfer capillary temperature was set to 225°C and 
the spray voltage was set to 1.6kV.  An Nth Order Double Play was created in 
Xcalibur v2.2.  Scan event one of the method obtained an FTMS MS1 scan 
(normal mass range; 240,000 resolution, full scan type, positive polarity, profile 
data type) for the range 300-2000m/z.  Scan event two obtained ITMS MS2 
scans (normal mass range, rapid scan rate, centroid data type) on up to twenty 
peaks that had a minimum signal threshold of 5,000 counts from scan event one.  
The lock mass option was enabled (0% lock mass abundance) using the 
371.101236m/z polysiloxane peak as an internal calibrant. 
 Proteome Discoverer v1.4.1.14 (Thermo Fisher Scientific) was used to  
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analyze the mass spectrometer data.  MS2 scan data were extracted from the 
Xcalibur RAW file, CID MS2 scans were searched in Mascot v2.5.1 (Matrix 
Science, Inc., Boston, MA, USA) and SequestHT, and results were collected in a 
single file.  The protein database UniprotKB Homo sapiens version 3/9/2016 
reference proteome canonical and isoform sequences, with cRAP database 
(thegpm.org) version 1/1/2012 appended to it, were used in the Mascot and 
SequestHT searches.  The resulting files from Proteome Discoverer were loaded 
into Scaffold Q+S v4.4.5 (Proteome Software, Inc., Portland, OR, USA).  The 
peptide false discovery rate was calculated with Scaffold Local FDR algorithm, 
and protein probabilities were calculated using the Protein Prophet algorithm.  
Results were annotated with human gene ontology information from the Gene 
Ontology Annotations Database (ftp.ebi.ac.uk). 
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RESULTS 
 The overarching goal of these experiments was to develop a strategy to 
isolate EGFR-containing early endosomes.  I hypothesized that biochemical 
enrichment of endosomes, followed by immunoisolation of an early endosome 
specific protein would lead to a preparation enriched with early endosome marker 
proteins but devoid of plasma membrane, late endosome, and endoplasmic 
reticulum candidate proteins. 
The experiments described below reflect my findings during the 
optimization process.  All experiments were performed using HeLa cells, a 
human adenocarcinoma cell line.  HeLa cells express physiologic levels of EGFR 
(~50,000 EGFRs/cell) [66], are amendable to cDNA transfection, adenoviral and 
lentiviral transduction, grow rapidly, and are relatively easy to culture.  The final 
protocol that was developed based upon these data is outlined in the Discussion 
section. 
EGFR associates with EEA1-positive vesicles upon EGF stimulation. 
 I first wanted to determine the extent of EGF-mediated EGFR 
redistribution to early endosomes in HeLa cells.  To monitor EGFR localization, 
HeLa cells were treated with EGF for increasing amounts of time, fixed, and 
subjected to indirect immunofluorescence probing for the EGFR (using a mouse 
monoclonal antibody, Ab-1 that recognizes the amino terminal, extracellular 
domain of the receptor) and Early Endosome Autoantigen 1 (EEA1) (using a 
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rabbit polyclonal antibody) (Figure 4).  Localization of the primary antibodies 
were visualized with Alexa 488-conjugated goat anti-rabbit (EEA1) and Alexa 
586-conjugated goat anti-mouse (EGFR) secondary antibodies.  Cells treated 
without EGF were used as a negative control. 
In the absence of EGF, the EGFR is localized primarily to the plasma 
membrane of cells.  The addition of EGF induces a time-dependent redistribution 
of EGFR that peaks with an accumulation of EGFR co-staining with early 
endosomes at 20 minutes.  These kinetics of endocytic trafficking are consistent 
with previous reports [67, 68].  Importantly, neither the intensity nor the 
distribution of EEA1 changes over time.  After 30 minutes of EGF treatment, 
there is a decrease in EGFR and EEA1 co-staining, which is consistent with 
reports that the EGFR is trafficked out of the early endosome 20-30 minutes after 
EGF stimulation [67, 68].   
DiI fluorescence can be used as a marker for early endosomes. 
Next, I wanted to determine if 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindo-
carbocyanine Perchlorate (DiI) could be used as a marker for early endosomes.  
DiI is a commercially available indocarbocyanine dye that binds to the plasma 
membrane and laterally diffuses into all lipid membranes.  The redistribution of 
the dye can be used as a measure of membrane trafficking.  When membrane 
domains containing the EGF:EGFR internalize, the DiI stained membrane would 
co-localize with the EGFR. 
HeLa cells were equilibrated to 4°C to halt membrane trafficking and 
incubated with 10μM DiI.  After the indicated amount of time, cells were warmed 
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Figure 4.  EGFR co-localization with EEA1-positive vesicles upon EGF 
stimulation.  HeLa cells were serum starved for 2 hours at 37°C and incubated 
with 10ng/mL EGF for 0’, 5’, 10’, 20’, and 30’.  Cells were fixed with 4% 
paraformaldehyde and stained for EGFR (Alexa-568) and EEA1 (Alexa-488) 
using indirect immunofluorescence.  Scale bar=20μm. 
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to 37°C and treated with 10ng/mL EGF for 10’.  The distribution of DiI stained 
membranes relative to EEA1 was determined (Figure 5).  Although there was an 
increase in total fluorescence that was proportional to the incubation time with 
DiI, there was no co-localization of DiI with early endosomes.  It is possible that 
the 4°C incubation may have reduced the ability of DiI to fully incorporate into 
membranes.  Further, the 10’ incubation at 37°C may not have been sufficient to 
re-equilibrate cells to a high enough temperature to re-initiate physiologic 
membrane trafficking. 
 Next, I asked if treating cells with EGF ligand and DiI concomitantly at 
37°C would enhance co-localization of DiI with early endosomes.  HeLa cells 
were incubated with 10μM DiI and 10ng/mL EGF at 37°C for 15’.  Cells were 
fixed and monitored for EGFR localization using indirect immunofluorescence.  
EGFR was monitored rather than EEA1 as I wanted to monitor newly formed 
endocytic internal compartments.  Cells treated without DiI and/or EGF were 
used as a negative control.  EGF treatment induced a redistribution of EGFR into 
punctate intracellular compartments.  DiI fluorescence was also observed in 
punctate intracellular compartments that co-localized with EGFR staining (Figure 
6). 
 Having confirmed that DiI labels compartments containing internalized 
EGFR after 15’ treatment with DiI and EGF at 37°C, I wanted to determine 
whether endosomal DiI labeling was restricted to early endosomes.  Serum-
starved HeLa cells were treated with 10uM DiI and 10ng/mL EGF for 15’.  Cells 
were then harvested using mechanical lysis and the PNS was subjected to a 
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Figure 5.  DiI does not co-localize with early endosomes when incubated at 
4°C.  HeLa cells were serum starved for two hours at 37°C and pre-treated with 
10μM DiI on ice (4°C) for the indicated amount of time, followed by treatment with 
10ng/mL EGF at 37°C for 10’.  Cells were fixed with 4% paraformaldehyde and 
stained for EEA1 (Alexa-488) using indirect immunofluorescence.  Scale 
bar=20μm.  
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Figure 6.  Co-localization of DiI and EGFR fluorescence at 37°C.  HeLa cells 
were serum starved for 2 hours at 37°C and incubated ±10μM DiI, ±10ng/mL 
EGF for 15’.  Cells were fixed with 4% paraformaldehyde and stained for EGFR 
(Alexa-488) using indirect immunofluorescence (DiI fluorescence was measured 
using a 568nm filter).  Scale bar=20μm. 
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17% Percoll gradient in 10mM triethanolamine/1mM EDTA/250mM sucrose 
(TES) buffer.  The gradient was fractionated into ~330μL (10 drop) fractions and 
assayed for DiI fluorescence on a plate reader.  A distinct peak of DiI 
fluorescence was measured at approximately the same Rf value in gradients of 
cells treated EGF (Figure 7).   
EGFR protein concentration peaks with TfnR protein concentration and DiI 
fluorescence in Percoll gradient fractions. 
In order to determine the endosome composition of the DiI peak fractions, 
immunoblotting was used to measure the distribution of early and late endosomal 
markers.  Using the same protocol described above, every other fraction of 
Percoll gradients were subjected to immunoblot for EGFR, TfnR (early/recycling 
endosome marker), and LAMP2 (late endosome/lysosome marker) (Figure 8A).  
In both the –EGF and +EGF samples, EGFR and TfnR peaked in the same 
fractions in which DiI fluorescence also peaked (Figure 8B), and LAMP2 was not 
present in these fractions.  Interestingly, the peak of EGFR was independent of 
EGF treatment.  Since the immunofluorescence data indicated that the 
endosomal accumulation of the EGFR was EGF dependent, this opened the 
possibility of plasma membrane contamination in these fractions. 
EEA1 can be targeted to purify early endosomes. 
In order to further enrich the early endosomes present in the Rf ~0.35-0.58 
Percoll fractions (~1.045g/mL density), I performed immunoisolation of these 
vesicles with various proteins predicted to be in the early endosomes: EEA1, 
EGFR, and TfnR.  Magnetic Dynabeads were utilized because they provide a 
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Figure 7. Relative DiI Fluorescence as a function of Percoll gradient 
fraction Rf Values.  HeLa cells were serum starved for 2 hours at 37°C and 
incubated with 10µM DiI ±10ng/mL EGF for 15’.  Cells were harvested using 
mechanical lysis and the PNS was loaded on a Percoll gradient and fractionated 
as outlined in the Materials and Methods.  DiI fluorescence of each fraction was 
measured on a plate reader (Ex- 530/25, Em-590/35).  Rf values were calculated 
as a function of total drops collected per sample.  Marker beads with known 
densities were also separated with a Percoll gradient and plotted against Rf 
values.  Fractions decrease in density from left to right (1.0-0.0).  Closed circles 
on the x-axis represent density bead migration (Rf ~0.91=1.109g/mL, 
~0.88=1.070g/mL, ~0.84=1.057g/mL, ~0.63=1.049g/mL, ~0.25=1.042g/mL).  
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Figure 8.  EGFR containing compartments migrate with DiI-positive and 
TfnR-positive compartments in Percoll gradients.   
A. Equivalent volumes from every other fraction of Percoll gradients from HeLa 
cells treated with 10µM DiI, ±10ng/mL EGF were loaded and resolved on a 7.5% 
SDS-PAGE.  Membranes were immunoblotted for EGFR, TfnR, and LAMP2. 
Immunoblots were imaged using enhanced chemiluminescence.  B.  Relative 
intensity of the +EGF immunoblots in A. calculated using Image J Software.  
Shaded region=Rf values where DiI fluorescence peaked in these samples.  
Circles on the x-axis represent density bead migration (Rf ~0.91=1.109g/mL, 
~0.88=1.070g/mL, ~0.84=1.057g/mL, ~0.63=1.049g/mL, ~0.25=1.042g/mL). 
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rapid, gentle, and high-throughput technique for affinity purification that would 
maximize the likelihood of keeping endosomes intact.  As an initial test of the 
efficiency of the antibodies, each was separately conjugated to Protein G 
Dynabeads and incubated with the PNS (from cells harvested by mechanical 
lysis) of HeLa cells treated ±10ng/mL EGF.  Three antibodies were selected 
based on the manufacturer’s rating for its IP capabilities and its protein target’s 
association with early endosomes.  The antibodies tested were targeted to:  the 
C-terminus of EGFR (sc-03, Santa Cruz), TfnR (BD Biosciences), and EEA1 
(Cell Signaling).  The pass through (PT) is defined as the remaining sample that 
did not bind to the beads, and the elution (E) is defined as the sample that bound 
to the beads after incubation (Figure 9).   
The sc-03 and TfnR antibodies did not effectively pull down EGFR, TfnR, 
or LAMP2.  The EEA1 antibody pulled down EGFR in the +EGF treated cells but 
not in cells that were not treated with EGF.  This is consistent with the notion that 
EGF:EGFR complexes are trafficked to the early endosome.  Further, the EEA1 
antibody yielded an approximately 50% pull down of TfnR, and virtually no pull 
down of LAMP2.   
Based on these results, the EEA1 antibody was selected to 
immunoprecipitate early endosomes from Percoll gradient fractions.  I 
hypothesized that affinity purification after density gradient fractionation would 
increase the yield of early endosomes, as they are enriched within the fractions, 
and decrease the amount of plasma membrane and late endosomal markers.   
Serum starved HeLa cells were treated with 10μM DiI ±10ng/mL EGF for  
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Figure 9.  EEA1 mAb conjugated to Protein G Dynabeads precipitates early 
endosome-specific proteins.  HeLa cells were serum starved for 2 hours and 
incubated ±10ng/mL EGF for 15’.  Cells were harvested using mechanical lysis 
and the PNS was incubated at 4°C with rotation for one hour with the specified 
antibody pre-conjugated to Protein G Dynabeads.  The beads were washed in 
buffer and eluted as outlined in the Materials and Methods.  Samples were 
loaded based on percent of the total sample volume (12.5% PT, 1.25% PNS, 
100% E) and proteins were resolved on a 7.5% SDS-PAGE and immunoblotted 
with the indicated primary antibody.  PT=pass through; E=elution. 
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15’.  Cells were then harvested using mechanical lysis and subjected to a 17% 
Percoll gradient.  Gradients were fractionated, and DiI-positive peak fractions 
were pooled and immunoisolated with EEA1-conjugated Protein G Dynabeads.  
Samples were then immunoblotted using the indicated primary antibodies 
(Figure 10). 
Approximately 50% of TfnR was pulled down, EGFR was only pulled down 
in the EGF treated sample, and LAMP2 did not appear to be precipitated.  EEA1 
was almost 100% pulled down in the elution, suggesting that using the EEA1 
antibody for affinity purification is highly effective.   
Plasma membrane and Endoplasmic Reticulum contamination of Percoll 
gradient fractions. 
Although EGFR was precipitated in the EGF treated sample in Figures 9 
and 10, there was still a significant fraction of EGFR remaining in the pass 
through.  To determine if this excess EGFR in the pass through was an artifact of 
contamination from other organelles, particularly plasma membrane and 
endoplasmic reticulum (ER), immunoblot membranes from previous experiments 
were re-probed for both a plasma membrane specific protein (Na/K-ATPase) and 
an ER specific protein (Calnexin) (Figure 11).   
Previously probed membranes from a Percoll gradient experiment (Figure 
8) and an early endosome affinity purification experiment (original data not 
shown) were stripped and re-probed for Na/K-ATPase and Calnexin.  Briefly, 
membranes were stripped of antibodies by rocking in stripping buffer (0.06M Tris, 
0.07M SDS, 0.7% BME, pH 6.8) at 50°C for 30’, followed by extensive washing in 
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Figure 10.  Affinity purification of early endosomes from Percoll gradient 
fractions.  Percoll gradient fractions of HeLa cells treated with 10μM DiI 
±10ng/mL EGF were pooled based on DiI fluorescence peaks.  Affinity 
purification was performed as outlined in the Materials and Methods.  Samples 
were loaded based on percent of total sample volume (5% PT, 50% E, & 2.5% 
WCL) and proteins were resolved on a 7.5% (EEA1 & TfnR) and 12% (EGFR & 
LAMP2) SDS-PAGE.  Membranes were immunoblotted for early and late 
endosomal proteins using the indicated primary antibodies.  WCL=whole cell 
lysates, PT=pass through, E=elution, IP=immunoprecipitation. 
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TBST.  Membranes were blocked overnight in 5% milk at 4°C and immunoblotted 
using the indicated primary antibodies.   
Calnexin was present in similar levels throughout the gradient, suggesting 
that ER contamination was present, but non-specific (Figure 11A).  However, 
Na/K-ATPase protein levels had distinct peaks within the gradient.  These 
fractions corresponded to the same peak fractions of DiI, TfnR, and EGFR from 
this experiment (see Figure 8) and are consistent with the notion that plasma 
membranes are enriched with early endosomes.  Despite the presence of both 
ER and plasma membrane contamination in these peak fractions, Calnexin and 
Na/K-ATPase were not present in the elution after affinity purification of pooled 
Percoll gradient fractions (Figure 11B).  However, since the plasma membrane 
contamination corresponded to the DiI peaks used to pool early endosomes, a 
discontinuous sucrose gradient was used to remove plasma membrane 
contamination from the PNS. 
Discontinuous sucrose gradients separate plasma membrane and 
intracellular vesicles. 
A discontinuous sucrose gradient, commonly referred to as a step 
gradient, was used to remove plasma membrane fragments from harvested cells.  
While Percoll gradients are a type of continuous gradient created during 
centrifugation, a step gradient is prepared prior to centrifugation and yields 
distinct fractions between each layer.  For this particular sucrose gradient, a step 
gradient with 60%, 38%, and 5% sucrose was used to separate intracellular 
vesicles and plasma membrane.   
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Figure 11.  Plasma membrane and ER contamination of Percoll gradient 
fractions.  A. Immunoblot membranes from a previous Percoll gradient were 
stripped and re-probed for Calnexin and Na/K-ATPase (Sigma).  See Figure 8 for 
experimental conditions.  B.  Immunoblot membranes from a previous affinity 
purification experiment were stripped and re-probed for Calnexin and Na/K-
ATPase (Sigma).  Samples from the original immunoblot experiment were 
collected from HeLa cells lysed with mechanical lysis followed by Percoll gradient 
fractionation in Percoll buffer.  Percoll gradient fractions were pooled based on 
DiI fluorescence and subjected to affinity purification with an EEA1 antibody 
conjugated to Protein G Dynabeads.  Samples were loaded based on total 
sample volume (PT=5%, E=50%, WCL=1.25%) and proteins were resolved on a 
10% SDS-PAGE. 
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Serum starved HeLa cells were incubated ±10ng/mL EGF for 15’.  Cells 
were harvested via a form of osmotic lysis and scraping as outlined in the 
Materials and Methods.  Lysates were then loaded on top of the sucrose gradient 
(i.e. on top of the 5% sucrose layer) and centrifuged.  Fractions were collected at 
both the 5%/38% interface, referred to as “vesicles”, and the 38%/60% interface, 
referred to as “membranes”.  The fractions were then immunoblotted for markers 
of early and late endosomes as well as plasma membrane (Figure 12).  
EEA1 was detected exclusively in the vesicles fractions.  EGFR protein 
concentrations were higher in the vesicles fraction compared to the membranes 
fraction in both EGF treated and untreated cells.  There was also an increase in 
EGFR in the vesicles fraction after EGF treatment.  TfnR and LAMP2 were both 
more concentrated in the vesicles fractions of both samples.  Although Na/K-
ATPase was also more concentrated in the vesicles fractions, there was still a 
distinct (albeit reduced) population of the protein within the membranes fraction.  
Discontinuous sucrose gradient followed by continuous Percoll gradient 
fractionation yields discrete early endosome enrichment. 
 Due to the distinct separation of endosomal marker proteins into the 
vesicles fractions and plasma membrane marker proteins into the membranes 
fractions on the sucrose gradient, I wanted to know if loading the vesicles 
fractions onto a Percoll gradient would result in diminished plasma membrane 
contamination in the early endosome fractions.  Serum starved HeLa cells were 
treated with 10ng/mL EGF for 15’ immediately prior to harvest.  Cells treated 
without EGF were used as a negative control.  Cells were harvested and loaded  
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Figure 12.  Discontinuous sucrose gradient separates plasma membrane 
and vesicle marker proteins.  HeLa cells were serum starved for two hours, 
followed by 15’ incubation with ±10ng/mL EGF.  Cells were harvested and 
lysates were loaded on a discontinuous sucrose gradient as outlined in the 
Materials and Methods.  Samples were loaded based on total sample volume 
(13% of V, M, & L) and resolved on a 7.5% SDS-PAGE.  Membranes were 
immunoblotted using the indicated primary antibody.  V=vesicles fraction 
(5%/38% interface), M=membranes fraction (38%/60% interface), L=lysates. 
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onto a pre-formed sucrose step gradient and centrifuged as outlined in the 
Materials and Methods.  Vesicles fractions were collected and loaded onto a 17% 
Percoll gradient adjusted to a final concentration of 0.25M sucrose.  Sucrose 
gradient and Percoll gradient fractions were immunoblotted for markers of early 
endosomes, late endosomes, and plasma membrane, as well as EGFR (Figure 
13). 
 The sucrose gradient separated approximately 55% of plasma membrane 
proteins into the membranes fraction, as evidenced by both Na/K-ATPase and 
EGFR (without EGF treatment) protein levels detected by immunoblot.  
Approximately 100% of EEA1 and LAMP2, positive controls for endosomes, were 
separated into the vesicles fraction.  After loading the vesicles fractions onto 
Percoll gradients, EEA1, EGFR, and Na/K-ATPase protein levels all peaked in 
fractions with an Rf value of approximately 0.15-0.30.  These Rf values 
corresponded with estimated vesicle densities of ~1.040g/mL.  LAMP2 protein 
concentration peaked in fractions with an Rf of approximately 0.87, and was also 
present in low levels in the EGFR, EEA1, and Na/K-ATPase peak fractions. 
Mass spectrometry analysis of purified early endosomes. 
 The ultimate goal of this thesis work is to isolate EGFR-containing early 
endosomes in order to analyze their protein make-up with mass spectrometry.  
Understanding the complete protein composition of early endosomes that contain 
activated EGFR will provide important insights into the influence of EGFR spatial 
regulation on downstream signaling.  Mass spectrometry will provide an unbiased 
platform to determine what proteins—including signaling, trafficking, scaffolding,  
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Figure 13.  Sucrose gradient removal of plasma membrane reduces Percoll 
gradient fraction contamination and improves early endosome enrichment.  
HeLa cells were serum starved at 37°C for 2 hours and incubated with ±10ng/mL 
EGF for 15’ immediately prior to harvest.  The PNS was loaded onto a 
discontinuous sucrose gradient as outlined in the Materials and Methods.  
Collected “vesicles” fractions were subsequently loaded onto an isotonic 17% 
Percoll gradient as outlined in the Materials and Methods.  A.  Immunoblots of 
sucrose gradient fractions from –EGF treated HeLa cells.  Samples were loaded 
2% of total sample volume and resolved on a 7.5% SDS-PAGE, followed by 
immunoblotting with indicated primary antibodies.  V=vesicles fraction, 
M=membranes fraction, L=lysates.  B.  Relative intensity of the immunoblots in 
A, estimated using Image J software.  Measurements were normalized by setting 
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the total band intensity of the V and M fractions equal to one for each 
immunoblot.  C.  Immunoblots of sucrose gradient “vesicles” fractions 
fractionated on a Percoll gradient.  Every other fraction was loaded 
(approximately 25% of the total volume per fraction) and resolved on a 7.5% 
SDS-PAGE and immunoblotted using the indicated primary antibodies.  D.  
Relative intensity of the immunoblots in C, estimated using Image J software.  
Circles on the x-axis represent density bead migration (Rf ~0.92=1.109g/mL, 
~0.90=1.070g/mL, ~0.86=1.057g/mL, ~0.53=1.049g/mL, ~0.28=1.042g/mL). 
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etc.—are associated with early endosomes that do and do not contain EGFR.  In 
order to determine if our affinity purification process is robust and sensitive 
enough for mass spectrometry analysis, I performed an affinity purification using 
EEA1 mAb on PNS extracted from HeLa cells treated with and without EGF.
 Serum starved HeLa cells were treated with or without 10ng/mL EGF for 
15’ immediately prior to harvest.  Cells were harvested using the harvest method 
in the sucrose gradient protocol as outlined in Materials and Methods section 
with minor modifications.  Briefly, a PNS was created by passaging cells through 
a syringe and 22G needle, followed by centrifugation at 800 x g to pellet nuclei 
and debris.  The PNS from each sample was incubated with Protein G 
Dynabeads pre-conjugated with EEA1 mAb as outlined in the Materials and 
Methods.  The beads elution and pass through were resolved on a 12% SDS-
PAGE and the gel was Coomassie stained for protein detection.  The elution, 
pass through, and PNS were also resolved on a separate 7.5% SDS-PAGE and 
immunoblotted for EEA1, LAMP2, Na/K-ATPase, and EGFR (Figure 14). 
 There was strong Coomassie protein staining in the pass through of both 
samples, and greatly reduced staining in the elution of both samples (Figure 
14A).  Although faint, there appears to be distinct protein bands in the +EGF 
elution that are not in the –EGF elution at molecular weights of approximately 
200kD, 110kD, and 60kD.  The majority of EEA1 is present in the elution of both 
–EGF and +EGF samples, and there is virtually no LAMP2 or Na/K-ATPase 
present in the elutions (Figure 14B).  There is also an increase in EGFR in the 
elution of the EGF treated sample compared to the EGF untreated sample. 
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Figure 14.  Affinity purification of early endosomes from HeLa cell PNS.  
Serum starved HeLa cells were treated ±10ng/mL EGF for 15’ and harvested 
with hypotonic lysis in 1mM Tris, 2mM EDTA followed by scraping.  Cells were 
passaged through a 22G needle 20 times and a PNS was created via 
centrifugation at 800 x g for 3’.  The PNS was incubated with EEA1-bound 
Protein G Dynabeads for 1 hour at 4°C with rotation.  The beads elution and pass 
through were collected and diluted in sample buffer for analysis.  A.  Samples 
were loaded by volume (2.5% PT, 50% E) and resolved on a 12% SDS-PAGE.  
The 12% gel was stained with Coomassie and imaged using a Fotodyne imaging 
system.  Molecular weight marker proteins are labeled with their respective 
molecular weight in kilodaltons.  –=no EGF, +=10ng/mL EGF treatment, PT=pass 
through, E=elution.  B.  Samples were loaded by volume (2.5% PT, 50% E, 
1.25% PNS) and resolved on a 7.5% SDS-PAGE, followed by immunoblotting 
with the indicated primary antibodies. 
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The coomassie stained gel in Figure 14A was digested and proteins were 
extracted from both of the elution lanes for liquid chromatography/mass 
spectrometry (LCMS) analysis, as outlined in detail in the Materials and Methods.  
A very brief description of these results is depicted in Table 1.  A total of 269 
proteins were detected in the –EGF sample, and a total of 559 proteins were 
detected in the +EGF sample.  Of the two samples, there was a convergence of 
221 proteins present in both samples.  As such, there were only 48 unique 
proteins in the –EGF sample, and 338 unique proteins in the +EGF sample 
(Table 1).  The most abundant protein detected was TfnR, and the second most 
abundant protein detected was EEA1 in both samples.   
 I performed an initial analysis of the mass spectrometry data by searching 
for EGFR and its known signaling effectors detected within the +EGF sample.  
EGFR was detected in very low levels in this sample, however, none of the major 
effectors (direct interacting proteins as well as downstream effectors) of EGFR 
that have been previously shown to associate with EGFR in endosomes were 
detected in the sample (e.g. Shc, Grb2, mSOS, MEK, Src, etc.) (data not shown).  
However, there were notable differences in the total number of proteins involved 
in important cellular processes including proteasomal degradation, translation, 
signaling, and trafficking (Tables 1 & 2).  Overall, there was an increase in the 
number of proteins detected that are associated with each of these processes in 
the +EGF sample compared to the –EGF sample.  There were also several 
candidate proteins that were detected in the +EGF sample that were not detected 
in the –EGF sample that have been associated with EGFR signaling, including: 
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Table 1.  Number of proteins detected by mass spectrometry of early 
endosomes isolated from HeLa cells treated with and without EGF. 
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Table 2.  RAB proteins detected by mass spectrometry of early endosomes 
isolated from HeLa cells treated with and without EGF. 
Σ#PSMs=the total number of identified peptide sequences for the given protein 
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Protein Kinase C-delta (PKCΔ), Rac1, Cdc42, and CSN6 & 7.   
There was an increase in expression of all of the RAB family proteins in 
the +EGF sample compared to the –EGF sample (Table 2).  Several new RAB 
family members were detected in the +EGF sample.  RAB6, RAB7, RAB13, and 
RAB34 were all present in the +EGF but not the –EGF samples, and are involved 
in Golgi to ER transport, late endosome maturation, the assembly of tight 
junctions, and macropinocytosis, respectively [69].  The number of proteins were 
counted in each group by searching for key words within the complete list of 
proteins detected per sample.   
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DISCUSSION 
 The overall purpose of this work was to develop and optimize a protocol 
for enriching and isolating early endosomes in order to study EGFR signaling 
from early endosomes in HeLa cells.  This was achieved by testing and 
combining various subcellular fractionation techniques from published methods.  
To begin, fluorescence microscopy was used to support the biochemical basis of 
the proposed work:  that EGFR internalizes into early endosomes upon ligand 
stimulation (Figure 4).  Our results were consistent with previous reports that 
EGFR traffics into early endosomes 20’ after ligand stimulation, after which the 
receptor traffics into late endosomes [67, 68].  
Next, I wanted to test the ability of a commercially available lipophilic 
tracer dye, DiI, to label early endosomes.  DiI is a fluorescent dye with a high 
affinity for all lipids that laterally diffuses into plasma membranes, and has been 
used as a membrane tracer dye for many years [70-72].  Because the process of 
subcellular fractionation is necessary for isolating endosomes, using a marker for 
the target organelle was highly desirable.  The use of a fluorescent dye would 
provide a non-invasive and qualitative means for measuring the migration of 
early endosomes within a density gradient.  The fluorescence of gradient 
fractions can be quickly measured on a plate reader to determine the 
fluorescence peak.  These fractions could theoretically then be subjected to 
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affinity purification to isolate the DiI-labeled early endosomes.  After determining 
the optimum DiI incubation conditions in HeLa cells (Figures 5 & 6), cells treated 
with DiI and EGF concomitantly were fractionated on a Percoll gradient and the 
fluorescence peak was measured (Figure 7).  Biochemical assays confirmed that 
the DiI fluorescence peak in the gradient fractions co-localized with the peaks of 
EGFR and TfnR protein expression (Figure 8).  These protein peaks likely 
represent early endosomes, as TfnR is constitutively recycled to early 
endosomes from the plasma membrane and EGFR internalizes with EGF 
treatment [46].   
Unfortunately, EGFR also peaks in the same fractions without EGF 
treatment (Figure 8).  This is consistent with the EGFR peak representing EGFR 
from the plasma membrane or other organelles.  However, because the next step 
in organelle isolation is immunoisolation, I supposed that low level contaminants 
could be removed.  Rf values of the EGFR peak fractions were calculated to 
contain vesicles with a density of ~1.045g/mL.  According to Kornilova et al., 
early endosomes have a density of ~1.035-1.042g/mL, and late endosomes have 
a density of ~1.048-1.060g/mL [45].  While the DiI fluorescence/EGFR peak was 
not in the appropriate density range for either early or late endosomes, it was 
presumed possible that the DiI peak represented early endosomes in the 
gradient.   
 As stated, the next step of purifying early endosomes from the Percoll 
gradient peak fractions was to use affinity purification with early endosome 
specific markers.  Three antibodies were tested for their ability to 
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immunoprecipitate early endosomes (Figure 9).  An EEA1 monoclonal antibody 
was selected from this preliminary screen of antibodies, as its use resulted in the 
successful precipitation of TfnR and EGFR (only with EGF treatment), but not 
LAMP2.  This strategy was then utilized to enrich early endosomes from the DiI 
fluorescence peaks of Percoll gradient fractions (Figure 10).  This resulted in the 
immunoprecipitation of TfnR, EEA1, and EGFR (only with EGF treatment), but 
not LAMP2.  However, it was noted that there was a significant amount of EGFR 
remaining in the pass through of both EGF treated and untreated samples.  
Although the affinity purification was effective, the majority of EGFR was not 
eluted with the early endosomes.  This again suggests the presence of other 
organelle contamination within the Percoll gradient peak fractions.   
If the use of DiI is a proper measure of early endosomes within the 
gradient, the pass through/pooled gradient fractions should be enriched in early 
endosomes.  Due to the high efficiency of the affinity purification as measured by 
EEA1 in the elution, it is unlikely that the EGFR remaining in the pass through is 
associated with early endosomes.  Further, there is a significant amount of EGFR 
in the –EGF sample pass through as well.  The majority of EGFR in unstimulated 
cells is localized to the plasma membrane [3, 30, 73].  This suggests that there is 
significant plasma membrane contamination within the Percoll gradient peak 
fractions.  This is also evidenced by the large amount of EGFR in the Percoll 
gradients of EGF untreated samples in Figure 8A.  Because DiI labels all lipid 
membranes, it is also possible that the DiI peak that co-localizes with EGFR 
peaks in the immunoblots are representative of plasma membrane fragments in 
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the gradient, as well as other organelle contamination such as ER, rather than 
early endosomes.  Due to the presence and pull down of early endosome-
specific proteins from these peak fractions (Figure 10), it was concluded that 
early endosomes were present.  However, early endosomes were not 
necessarily enriched in the pooled gradient fractions.  Interestingly, TfnR protein 
levels also peaked in the same fractions as EGFR and DiI fluorescence (Figure 
8B).  However, TfnR is not an ideal early endosome marker as it is constitutively 
recycled to and from the plasma membrane.  As such, the next step was to 
determine the extent of plasma membrane and ER contamination within the 
Percoll gradients, and if it interfered with the use of DiI as a marker of early 
endosomes within these gradients. 
Calnexin was used as a positive control for ER, and Na/K-ATPase was 
used as a positive control for plasma membrane, as both of these proteins are 
specifically localized to those organelles, respectively [74, 75].  Diffuse and non-
specific ER contamination was detected throughout the Percoll gradients, and a 
distinct peak of plasma membrane contamination was detected (Figure 11).  
Fortunately, though these protein markers were present in the pooled Percoll 
gradient fractions, they were not precipitated upon affinity purification.  However, 
the peak of Na/K-ATPase contamination corresponded to the same fractions in 
which EGFR, TfnR, and DiI peaked in all previous experiments.  Due to the 
strong plasma membrane contamination within the peak DiI fractions, the DiI 
staining of the plasma membrane is likely much stronger and masking that of the 
early endosomes in the gradient.  If DiI is to be used as a marker for the fractions 
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containing early endosomes that will be pooled for affinity purification, plasma 
membrane contamination must be removed or at least reduced from the samples 
in order to reveal the true peak of DiI fluorescence from early endosomes. 
A discontinuous sucrose gradient was used as a means to separate 
plasma membrane fragments from intracellular vesicles of HeLa cells.  Although 
not all of the plasma membrane proteins were separated from the vesicles, 
approximately 25% of the Na/K-ATPase protein concentration was measured in 
the membranes fractions (Figure 12).  This suggests that there is in fact 
separation of plasma membrane proteins using this protocol, although it is not a 
100% enrichment.  Further, EEA1 was found exclusively in the vesicles fractions, 
suggesting that there was no early endosome sample loss into the membranes 
fraction with this protocol.  The DiI fluorescence of the vesicles and membranes 
fractions was also measured, and it was determined that the DiI fluorescence 
intensity was more directly correlated to plasma membranes than to early 
endosomes.  As such, DiI was no longer used as a marker of early endosomes. 
The next step was to test the use of the sucrose gradient prior to Percoll 
gradient fractionation to reduce plasma membrane contamination.  The results 
from this experiment revealed a new profile of early endosome and plasma 
membrane proteins within the fractions compared to previous Percoll gradients 
(Figure 13).  The Rf values associated with both plasma membrane and early 
endosome marker proteins were ~0.15-0.30, and the calculated densities of 
these fractions were ~1.040g/mL.  A miscalculation resulted in using sucrose at a 
concentration of ~0.16M.  The proper sucrose concentration of a Percoll gradient 
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should be isotonic, or 0.25M.  This discrepancy accounts for the previous density 
calculations of early endosome protein-containing fractions that did not agree 
with the known densities of early endosomes [45].  As such, the use of a sucrose 
step gradient prior to Percoll gradient fractionation yields reduced plasma 
membrane contamination and a distribution of early endosome proteins that 
corresponds with proper early endosome density.  These results also correlate 
with the distribution of EGFR in Percoll gradients within the literature [60, 76]. 
The final test performed in this thesis work was mass spectrometry on 
affinity purified early endosomes.  Before performing mass spectrometry on early 
endosomes isolated using the finalized protocol, we first wanted to test the 
specificity and sensitivity of the affinity purification step.  Post-nuclear 
supernatants collected from HeLa cells treated with and without EGF ligand were 
subjected to affinity purification, followed by LCMS analysis.  While the overall 
goal of this research is to analyze EGFR signaling effectors in early endosomes, 
this initial experiment was a preliminary test of our abilities to analyze isolated 
early endosomes.   
We were able to successfully enrich early endosomes with minimal 
contamination from other organelles (Figure 14).  The most abundant proteins 
detected in both samples of endosomes were TfnR and EEA1, both of which 
were used as positive controls for early endosomes.  Na/K-ATPase, Calnexin, 
and LAMP2 were used as negative controls.  Na/K-ATPase was not detected in 
either sample, however, LAMP2 and Calnexin were detected in the +EGF 
sample, albeit at very low abundance.  This suggests there was no plasma 
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membrane contamination in the enriched samples, however, there was a small 
amount of late endosome and ER contamination in the +EGF sample.  
Encouragingly, EGFR was detected only in the +EGF sample, supporting the fact 
that EGF treatment leads to EGFR endocytosis into early endosomes.  However, 
the amount of EGFR detected was very low, and specific effector and scaffold 
proteins that are known to associate with EGFR in early endosomes upon ligand 
stimulation—Shc, Grb2, mSOS, MEK2, etc.—were not detected in this sample. 
While several specific EGFR effectors that are known to associate with 
EGFR in early endosomes were not detected, several other proteins that are 
involved in EGFR signaling were detected in the +EGF sample.  For example, 
PKCΔ was present in the EGFR-containing early endosomes.  PKC has been 
shown to inhibit EGFR signaling via MAPK [77].  Rac1—a Rho family GTPase 
that is downstream of EGFR—and CDC42—a cell cycle regulator that is also 
downstream of EGFR—were detected in the +EGF sample.  Both Rac1 and 
CDC42 are positive regulators of EGFR signaling that are involved in cell motility 
and cell cycle progression [78].  CSN6 and CSN7 are subunits of the COP9 
signalosome complex, which is involved in the ubiquitin-proteasome pathway.  
Both of these subunits were also detected in the +EGF sample.  CSN6 was 
recently linked to the progression of colorectal cancer via a CSN6-ERK2 
interaction [79].   
We detected in the EGF-treated sample an increase in the number of 
proteins involved in several important cellular processes, including translation, 
proteasomal degradation, and signaling (Table 1).  There was also an increase in 
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the number and type of RAB proteins detected in the +EGF sample compared to 
the untreated sample (Table 2).  Interestingly, there was an increase in the 
number and type of RABs associated with late endosomes in the +EGF sample, 
suggesting that the early endosomes were in the process of maturing into late 
endosomes [80].  This is consistent with EGFR being trafficked into “dynamic” 
early endosomes, which are associated with microtubules and rapidly mature into 
late endosomes [46]. 
In this thesis work, I was able to modify published protocols to enrich early 
endosomes.  We were also able to successfully isolate endosomes from HeLa 
cells treated with and without EGF ligand and use mass spectrometry to analyze 
their protein make-up.  
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SUMMARY AND CONCLUSIONS 
The overarching goal of the work performed in this thesis was to develop 
an early endosome isolation protocol in order study EGFR effector signaling from 
this compartment.  Current methods for endosome isolation in the literature were 
utilized as a starting point for this work.  Several variations of subcellular 
fractionation were tested and optimized to achieve a final protocol that results in 
discrete enrichment of early endosomes with minimal contamination from other 
organelles.  The affinity purification step was also tested and shown to be robust 
and highly specific for the purification of early endosomes.  This step of the 
procedure was also sensitive enough for proteomics analysis via LCMS of the 
purified compartments.  This analysis revealed distinct differences in the protein 
composition of endosomes isolated from cells stimulated with and without EGF.  
In the future, mass spectrometry analysis will be performed on early endosomes 
isolated using the finalized enrichment protocol in order to study the effects of 
EGF treatment on early endosome protein composition and EGFR downstream 
signaling. 
Strengths of This Work 
 A major strength of this work is in its use of HeLa cells.  This cell line 
expresses EGFR at levels similar to what has been measured in normal human 
epithelial tissues (~50,000 EGFRs per cell), allowing us to correlate findings in 
these cells with the physiologic activity of EGFR.  To this same end, physiologic/ 
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low levels of EGF ligand were used to stimulate EGFR activation (10ng/mL).  
Further, HeLa cells grow rapidly, permitting the generation of large populations of 
cells, if they are required for subsequent endosome enrichment.   
Another important strength of this work is that we were able to isolate 
early endosomes without introducing exogenous factors into the cells.  While it is 
generally acceptable to use cell lines that have been genetically altered to 
enhance detection and capture of the target protein of interest, we were able to 
enrich early endosomes without the use of epitope tags or transfection reagents.  
As a result of this, the isolated early endosomes are physiologically relevant.  
The proteomics data obtained from these compartments can thus be taken at 
face value, without concerns about non-physiologic changes in their structure or 
function. 
Limitations of This Work 
 One of the few limitations of this thesis work is that it was performed using 
an in vitro cell line.  A major drawback to using tissue culture rather than animals 
is that the results cannot be correlated to the whole organism level.  In vitro cell 
lines lack the complex interplay of signaling that occurs within organisms and 
even tissues.  Tissue culture models are ideal for preliminary studies, however, 
isolating early endosomes from an animal would provide an even more 
physiologically relevant analysis of EGFR signaling from these compartments.   
Future Directions 
 One of the most important experiments to perform moving forward will be 
to affinity purify early endosomes enriched using the finalized protocol with both 
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sucrose and Percoll gradients.  This should provide a more robust precipitation of 
early endosomes and increased sensitivity for the detection of EGFR effectors 
with mass spectrometry.  In order to draw conclusions from the mass 
spectrometry analysis, we would need to repeat these experiments and 
determine if the results obtained are reproducible.  Once this has been 
completed, we will then be able to determine the extent of the effects of EGFR 
spatial regulation on downstream signaling.  Not only will we be able to 
determine what effectors co-localize with EGFR in early endosomes upon ligand 
activation, but we will also use this information to test how the subcellular 
localization of effectors changes downstream signaling.  Using stably transfected 
cell lines, we will be able to change the cellular localization of EGFR effectors 
and determine the physiological role that effector localization plays in EGFR 
signaling outcomes. 
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